- Home
- NUKK vs ADAP Comparison
NUKK vs ADAP Comparison
Compare NUKK & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUKK
- ADAP
- Stock Information
- Founded
- NUKK 2013
- ADAP 2008
- Country
- NUKK United States
- ADAP United Kingdom
- Employees
- NUKK N/A
- ADAP N/A
- Industry
- NUKK Blank Checks
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- NUKK Finance
- ADAP Health Care
- Exchange
- NUKK Nasdaq
- ADAP Nasdaq
- Market Cap
- NUKK 77.4M
- ADAP 75.5M
- IPO Year
- NUKK N/A
- ADAP 2015
- Fundamental
- Price
- NUKK $9.59
- ADAP $0.28
- Analyst Decision
- NUKK
- ADAP Buy
- Analyst Count
- NUKK 0
- ADAP 6
- Target Price
- NUKK N/A
- ADAP $1.35
- AVG Volume (30 Days)
- NUKK 597.5K
- ADAP 658.2K
- Earning Date
- NUKK 07-15-2025
- ADAP 08-11-2025
- Dividend Yield
- NUKK N/A
- ADAP N/A
- EPS Growth
- NUKK N/A
- ADAP N/A
- EPS
- NUKK N/A
- ADAP N/A
- Revenue
- NUKK N/A
- ADAP $179,639,000.00
- Revenue This Year
- NUKK N/A
- ADAP N/A
- Revenue Next Year
- NUKK N/A
- ADAP $35.48
- P/E Ratio
- NUKK N/A
- ADAP N/A
- Revenue Growth
- NUKK N/A
- ADAP 878.53
- 52 Week Low
- NUKK $1.30
- ADAP $0.20
- 52 Week High
- NUKK $78.32
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- NUKK 37.12
- ADAP 57.74
- Support Level
- NUKK $8.99
- ADAP $0.23
- Resistance Level
- NUKK $11.57
- ADAP $0.26
- Average True Range (ATR)
- NUKK 0.87
- ADAP 0.02
- MACD
- NUKK 0.00
- ADAP 0.00
- Stochastic Oscillator
- NUKK 21.55
- ADAP 92.22
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.